205 related articles for article (PubMed ID: 38386926)
1. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs.
Pal Choudhuri S; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Kim YJ; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Mazloom-Farsibaf H; Stanzione M; Wong KK; Hung YP; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
Cancer Discov; 2024 May; 14(5):804-827. PubMed ID: 38386926
[TBL] [Abstract][Full Text] [Related]
2. Acquired Cross-resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of
Choudhuri SP; Girard L; Lim JYS; Wise JF; Freitas B; Yang D; Wong E; Hamilton S; Chien VD; Gilbreath C; Zhong J; Phat S; Myers DT; Christensen CL; Stanzione M; Wong KK; Farago AF; Meador CB; Dyson NJ; Lawrence MS; Wu S; Drapkin BJ
bioRxiv; 2023 Jun; ():. PubMed ID: 37425738
[TBL] [Abstract][Full Text] [Related]
3. Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes.
Pongor LS; Schultz CW; Rinaldi L; Wangsa D; Redon CE; Takahashi N; Fialkoff G; Desai P; Zhang Y; Burkett S; Hermoni N; Vilk N; Gutin J; Gergely R; Zhao Y; Nichols S; Vilimas R; Sciuto L; Graham C; Caravaca JM; Turan S; Tsai-Wei S; Rajapakse VN; Kumar R; Upadhyay D; Kumar S; Kim YS; Roper N; Tran B; Hewitt SM; Kleiner DE; Aladjem MI; Friedman N; Hager GL; Pommier Y; Ried T; Thomas A
Cancer Discov; 2023 Apr; 13(4):928-949. PubMed ID: 36715552
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of A Patient-derived Xenotransplantation Animal Model for Small Cell Lung Cancer and Drug Resistance Model].
Zhu Y; Huang W; Wu Y; Jia L; Li Y; Chen R; Guo L; Chen Q
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):6-14. PubMed ID: 30674387
[TBL] [Abstract][Full Text] [Related]
5. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
[TBL] [Abstract][Full Text] [Related]
6. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Farago AF; Yeap BY; Stanzione M; Hung YP; Heist RS; Marcoux JP; Zhong J; Rangachari D; Barbie DA; Phat S; Myers DT; Morris R; Kem M; Dubash TD; Kennedy EA; Digumarthy SR; Sequist LV; Hata AN; Maheswaran S; Haber DA; Lawrence MS; Shaw AT; Mino-Kenudson M; Dyson NJ; Drapkin BJ
Cancer Discov; 2019 Oct; 9(10):1372-1387. PubMed ID: 31416802
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer.
Owonikoko TK; Zhang G; Kim HS; Stinson RM; Bechara R; Zhang C; Chen Z; Saba NF; Pakkala S; Pillai R; Deng X; Sun SY; Rossi MR; Sica GL; Ramalingam SS; Khuri FR
J Transl Med; 2016 May; 14(1):111. PubMed ID: 27142472
[TBL] [Abstract][Full Text] [Related]
8. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
9. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
10.
Grunblatt E; Wu N; Zhang H; Liu X; Norton JP; Ohol Y; Leger P; Hiatt JB; Eastwood EC; Thomas R; Ibrahim AH; Jia D; Basom R; Eaton KD; Martins R; Houghton AM; MacPherson D
Genes Dev; 2020 Sep; 34(17-18):1210-1226. PubMed ID: 32820040
[TBL] [Abstract][Full Text] [Related]
11. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
12. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
[TBL] [Abstract][Full Text] [Related]
13. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
[TBL] [Abstract][Full Text] [Related]
14. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
[TBL] [Abstract][Full Text] [Related]
15. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
17. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
[TBL] [Abstract][Full Text] [Related]
18. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
[TBL] [Abstract][Full Text] [Related]
19. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
[TBL] [Abstract][Full Text] [Related]
20. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
Tokgun O; Tokgun PE; Inci K; Akca H
Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]